Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.47 |
| ▸ | RXRA | P19793 | 7/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756468 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL6523576 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL25756467 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL29616653 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL3724868 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL24451647 | 1.00 | BACE1 (0.53) | BACE1NR1H2NR1H3RXRAIMPDH2 | |
| SCHEMBL3664778 | 0.89 | NR1H2 (0.51) | BACE1NR1H2NR1H3RXRA | |
| SCHEMBL25240372 | 0.89 | NR1H2 (0.51) | BACE1NR1H2NR1H3RXRA | |
| SCHEMBL6521416 | 0.89 | NR1H2 (0.51) | BACE1NR1H2NR1H3RXRA | |
| SCHEMBL26312430 | 0.89 | NR1H2 (0.48) | BACE1NR1H2NR1H3RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| WO-2023196307-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023177854-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| WO-2023109926-A1 | SPIROOXINDOLE COMPOUND AND USE THEREOF IN PREPARATION OF PROTEASE INHIBITOR AS ANTIVIRAL DRUG | 南京药石科技股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
| EP-4001279-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | Enanta Pharmaceuticals, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-9346805-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2240483-B1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8324221-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331734-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, PKD1, ACE2 | BACE1 4356/4885NR1H2 791/4885NR1H3 634/4885 |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | BACE1 2982/4885NR1H2 555/4885NR1H3 462/4885 |
| US-20230295175-A1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED SPIROOXINDOLE DERIVATIVES | ACE2, ACE, REN | BACE1 1644/4885NR1H2 461/4885NR1H3 499/4885 |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, PIK3CA | BACE1 1628/4885NR1H2 1663/4885NR1H3 1678/4885 |
| US-11325916-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | BACE1 2982/4885NR1H2 555/4885NR1H3 462/4885 |
| US-11319325-B1 | Macrocyclic spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | BACE1 3140/4885NR1H2 555/4885NR1H3 470/4885 |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | BACE1 2982/4885NR1H2 555/4885NR1H3 462/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | BACE1 2982/4885NR1H2 555/4885NR1H3 462/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | BACE1 2658/4885NR1H2 1088/4885NR1H3 883/4885 |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | BACE1 3739/4885NR1H2 460/4885NR1H3 445/4885 |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, AKT2 | BACE1 1617/4885NR1H2 1859/4885NR1H3 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.